Drug class profile · refreshed daily from federal data

Penem Antibacterial

3 molecules in this class, $134.3M combined CY2024 Part D spend across 407K claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 15 Oct 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Penem Antibacterial class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 3tracked in Part D
CY24 Part D spend: $134.3Mcombined across class
Total Rx claims: 407K155K unique beneficiaries
Generic mfrs (active): 15across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Ertapenem

Brand: ERTAPENEM · 264K Part D claims (CY24) · 107K beneficiaries · First FDA approval: 2001-11-21

5 generic mfrs 20 plans require PA

Low NADAC$26.63

→

Avg plan cost$28.10

Part D spend $108.0M 1× spread, current vs floor

Class share

80%

of class CY24 spend

View profile →

Meropenem

144K Part D claims (CY24) · 48K beneficiaries · First FDA approval: 2011-10-14

8 generic mfrs 40 plans require PA

Low NADAC$4.69

→

Avg plan cost$4.69

Part D spend $26.3M 1× spread, current vs floor

Class share

20%

of class CY24 spend

View profile →

Imipenem and Cilastatin

Brand: Imipenem and Cilastatin · — Part D claims (CY24) · First FDA approval: 1985-11-26

2 generic mfrs 44 plans require PA Discontinued

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.